scholarly journals Personalized at-home neurofeedback compared with long-acting methylphenidate in an european non-inferiority randomized trial in children with ADHD

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Stéphanie Bioulac ◽  
Diane Purper-Ouakil ◽  
Tomas Ros ◽  
Hilario Blasco-Fontecilla ◽  
Marie Prats ◽  
...  
Author(s):  
Diane Purper‐Ouakil ◽  
Hilario Blasco‐Fontecilla ◽  
Tomas Ros ◽  
Eric Acquaviva ◽  
Tobias Banaschewski ◽  
...  

2017 ◽  
Vol 174 (5) ◽  
pp. 459-467 ◽  
Author(s):  
Maria Sullivan ◽  
Adam Bisaga ◽  
Martina Pavlicova ◽  
C. Jean Choi ◽  
Kaitlyn Mishlen ◽  
...  

2011 ◽  
Vol 51 (5) ◽  
pp. 282
Author(s):  
Tjhin Wiguna ◽  
Sasanto Wibisono ◽  
Sudigdo Sastroasmoro ◽  
Fransiscus D. Suyatna

Objective To identify the cardiovascular effects of long-acting methylphenidate administered for twelve weeks in Indonesian children with ADHD.Methods This was an 18-week, time series study on children with ADHD who were given 20 mg of long-acting methylphenidate for twelve weeks. During the study period we made ten serial observations of the subjects, including before, during and 6 weeks following drug administration. We included drug naive children with ADHD between the ages of 7 – 10 years. Children with mental retardation and chronic physical or mental disorders were excluded. Blood pressure was measured by sphygmomanometer with a child’s cuff at the brachial artery. We also collected data on heart rate, side effects, complaints and other medications used during the study. Repeated analysis was performed on the data with a P level of 0.05.Results Twenty-one subjects were recruited for this study. Mean blood pressure fluctuated insignificantly during the research period, for both mean systolic and mean diastolic blood pressures (P=0.115 and P=0.059). Mean heart rate also fluctuated insignificantly (P=0.091). All fluctuations were within the normal ranges. During the study, there were complaints of dizziness, nausea, and gastrointestinal upset, but they were reportedly mild and disappeared before the second week of observation.Conclusion Administration of 20 mg long-acting methylphenidate for twelve weeks in children with ADHD altered mean blood pressures and heart rates, but within the normal range for children of their age. However, cardiovascular risk observation is still needed when administering methylphenidate to children with ADHD, especially for those using the medication long-term.[Paediatr Indones. 2011;51:282-7].


2016 ◽  
Vol 36 (2) ◽  
pp. 251-260 ◽  
Author(s):  
Lucas Machado ◽  
Rodolfo Anchieta ◽  
Paulo dos Santos ◽  
André Briso ◽  
Nick Tovar ◽  
...  

CHEST Journal ◽  
2020 ◽  
Vol 158 (6) ◽  
pp. 2493-2501 ◽  
Author(s):  
Ries J.M. van den Biggelaar ◽  
Anda Hazenberg ◽  
Nicolle A.M. Cobben ◽  
Michael A. Gaytant ◽  
Karin M. Vermeulen ◽  
...  

2019 ◽  
Vol 49 (5) ◽  
pp. 673-687 ◽  
Author(s):  
Erika K. Coles ◽  
William E. Pelham ◽  
Gregory A. Fabiano ◽  
Elizabeth M. Gnagy ◽  
Lisa Burrows-MacLean ◽  
...  

CNS Spectrums ◽  
2007 ◽  
Vol 12 (S6) ◽  
pp. 8-11 ◽  
Author(s):  
Thomas J. Spencer

AbstractAttention-deficit/hyperactivity disorder (ADHD) is a lifelong condition that begins in childhood and continues with adult manifestations related to the core symptoms. Approximately 50% to 75% of children with ADHD continue to meet criteria for the disorder as adolescents and adults. Adults with the disorder increasingly present to primary care physicians, psychiatrists, and other practitioners for diagnosis and treatment. Understanding the diagnosis of ADHD in adults requires knowledge of age-dependent decline of symptoms over time. Retrospective recall of symptoms and impairment are valid methods of diagnosing the disorder. ADHD is also a brain disorder with a strong neurobiologic basis, complex etiology, and genetic component. Genetic and environmental vulnerabilities give rise to abnormalities in the brain and subsequent behavioral and cognitive deficits, which may produce the symptoms associated with ADHD. Magnetic resonance imaging studies of ADHD have provided evidence that abnormalities in the brain are caused by the disorder itself rather than treatment of the disorder. Psychiatric comorbidity is common among patients with ADHD and tends to complicate treatment. Acute and long-term use of long-acting stimulant formulations (methylphenidate and amphetamine compounds) have shown robust efficacy and tolerability consistent with the treatment response established in children with ADHD. Non-stimulant medications have demonstrated efficacy as well, and may be preferred in patients with tic and substance use disorders.In this expert roundtable supplement, Timothy E. Wilens, MD, reviews the epidemiology and clinical presentation of adult ADHD. Next, Joseph Biederman, MD, provides an overview of recent advances in the neurobiology of ADHD. Thomas J. Spencer, MD, reviews stimulant treatment of adult ADHD, and Lenard A. Adler concludes with a discussion of non-stimulant trials in adult ADHD.


Sign in / Sign up

Export Citation Format

Share Document